BR1400-2
Phase 2Small molecule
Boryung Pharmaceutical Co., LtdBR1400-2 is one of 26 small molecule programs targeting Essential Hypertension. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
54 competitors in Essential Hypertension
#DrugCompanyPhaseTrials
1Zebeta
TevaApproved
Tekturna
Tibotec Pharmaceuticals, IrelandApproved
Bayer Aspirin
BayerApproved
Aldactone
PfizerApproved
Cialis
Eli LillyApproved
Rifadin
SanofiApproved
Cardura
VViatris Specialty LLC
Approved
Procardia
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Coumadin
AAbbott
Approved
Lanoxin
AAdvanz Pharma
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BR1400-2. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details